A global multicenter，randomized，double-blind，placebo -controlled， adaptive designed phase Ⅲ clinical trial to evaluate the efficacy， safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above
2022-07-19
عنوان الدراسة
A global multicenter，randomized，double-blind，placebo -controlled， adaptive designed phase Ⅲ clinical trial to evaluate the efficacy， safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above
داعم الدراسة
MOH / CanSino
دواء الدراسة
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
رقم بروتوكول الدراسة
CS-CTP-AD5NCOV-ⅢCo
حالة الدراسة
Rejected
موقع الدراسة
King Fahad Medical City (Riyadh)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。